Pfizer News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Pfizer Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Pfizer Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Pfizer from all sources in a single place.

Pfizer Ltd.

07 Dec 2025

5058.50

0.74%

Eli Lilly, Pfizer drugs added to China's first private insurance list

Business Standard

As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the inclusion of these drugs may ease the burden on state medical insurance

Pfizer Ltd. is trading below its 50 day SMA of 5127.8

Eli Lilly, Pfizer land on China's first private insurance list

Business Line | 07 Dec 2025

Pfizer Ltd.

17 Nov 2025, 08:09PM

5058.50

0.74%

Pfizer brings in Rimegepant, its novel Orally Disintegrating Tablet, to treat acute migraine

Business Line

Migraine poses a challenge in India, affecting around 213 million people annually

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Pfizer launches Rimegepant ODT in India to tap $200 mn migraine market

Business Standard | 17 Nov 2025, 07:44PM 1 more

Pfizer Ltd.

14 Nov 2025

5058.50

0.74%

Growth momentum accelerating

Buy: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Pfizer’s Q2FY26 revenue grew at a faster pace of 9.1% YoY, surpassing IPM growth of ~8%. Rebound in growth across key brands has helped the company grow faster in the otherwise prevalent sluggish growth scenario for acute therapies.

Pfizer Ltd. is trading below its 50 day SMA of 5127.8

Pfizer Ltd.

13 Nov 2025

5058.50

0.74%

Pfizer Share Price Jumps Over 6% As Q2 Net Profit Increases

NDTV Profit

Pfizer Ltd. share price rose as much as 6.45% to Rs 5,339 apiece, the highest level since Oct 30.

Pfizer Ltd. is trading below its 50 day SMA of 5127.8

Pfizer Ltd.

12 Nov 2025

5058.50

0.74%

Board Meeting

Pfizer Ltd - 500680 - Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial …

BSE India

Pursuant to Regulations 30 and 33 of the Listing Regulations, we submit herewith the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025, which were inter alia approved by the Board of Directors of the Company at their Meeting held today i.e., November 12, 2025, that commenced at 2.00 p.m. and concluded at 3.15 p.m.

pdf

Pfizer Ltd.

08 Nov 2025

5058.50

0.74%

Metsera accepts Pfizer's $10 billion acquisition bid in ongoing M&A battle

Business Standard

Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, sparking a strategic fight

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Pfizer Ltd.

03 Nov 2025

5058.50

0.74%

Board Meeting

Pfizer Ltd - 500680 - Board Meeting Intimation for Board Meeting To Consider And Approve The …

BSE India

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, November 12, 2025 inter alia, to consider, approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025.

pdf

Pfizer Ltd.

01 Nov 2025

5058.50

0.74%

Pfizer sues to stop rival bid for Metsera by Denmark's Novo Nordisk

Business Standard

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark's Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer's bid, which was announced in September. Metsera Inc has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes. Novo already has the treatments Wegovy and Ozempic on the market in those respective categories. Pfizer said the offer from Novo cannot be considered superior to its bid because it carries significant regulatory risk that makes it unlikely to be completed. Pfizer, which ended development of a potential pill to

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Pfizer Ltd.

09 Oct 2025

5058.50

0.74%

Pfizer-Trump deal: What it means for drug prices and pharma giants in US

Business Standard

Pfizer has pledged to make some medicines available at lower prices for the Medicaid programme and in return gained relief from immediate import tariffs